Polycomb-independent activity of EZH2 in castration resistant prostate cancer

被引：0
|
作者：
Kexin Xu
Zhenhua Jeremy Wu
Anna C Groner
Housheng Hansen He
Changmeng Cai
Edward C Stack
Massimo Loda
Tao Liu
Colm Morrissey
Robert L Vessella
Philip W Kantoff
Steven P Balk
X Shirley Liu
Myles Brown
机构：
[1] Dana-Farber Cancer Institute,Center for Functional Cancer Epigenetics
[2] Dana-Farber Cancer Institute and Harvard Medical School,Department of Medical Oncology
[3] Dana-Farber Cancer Institute and Harvard School of Public Health,Department of Biostatistics and Computational Biology
[4] Beth Israel Deaconess Medical Center and Harvard Medical School,Hematology
[5] Dana-Farber Cancer Institute,Oncology Division, Department of Medicine
[6] Harvard Medical School,Center for Molecular Oncologic Pathology
[7] King’s College London,Department of Pathology, Brigham and Women’s Hospital
[8] University of Washington Medical Center,Division of Cancer Studies
[9] Puget Sound VA Health Care System,Department of Urology
来源：
Epigenetics & Chromatin | / 6卷 / Suppl 1期
关键词：
Androgen Receptor; Acute Leukemia; Castration Resistant Prostate Cancer; Histone Methyltransferase; Methyltransferase Activity;
D O I：
10.1186/1756-8935-6-S1-O14
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
    Kim, Jung
    Lee, Yongik
    Lu, Xiaodong
    Song, Bing
    Fong, Ka-Wing
    Cao, Qi
    Licht, Jonathan D.
    Zhao, Jonathan C.
    Yu, Jindan
    CELL REPORTS, 2018, 25 (10): : 2808 - +
  • [22] Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
    Labaf, Maryam
    Li, Muqing
    Ting, Lily
    Karno, Breelyn
    Zhang, Songqi
    Gao, Shuai
    Patalano, Susan
    Macoska, Jill A. A.
    Zarringhalam, Kourosh
    Han, Dong
    Cai, Changmeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] Targeting EZH2 in neuroendocrine prostate cancer
    Puca, Loredana
    Gao, Dong
    Kossai, Myriam
    Marotz, Clarisse
    Mosquera, Juan Miguel
    MacDonald, Theresa Y.
    Park, Kyung
    Rao, Rema
    Sboner, Andrea
    Chen, Yu
    Rubin, Mark A.
    Beltran, Himisha
    CANCER RESEARCH, 2015, 75
  • [24] EZH2 accompanies prostate cancer progression
    Xin, Li
    NATURE CELL BIOLOGY, 2021, 23 (09) : 934 - 936
  • [25] EZH2, an epigenetic driver of prostate cancer
    Yeqing Angela Yang
    Jindan Yu
    Protein & Cell, 2013, 4 (05) : 331 - 341
  • [26] EZH2 accompanies prostate cancer progression
    Li Xin
    Nature Cell Biology, 2021, 23 : 934 - 936
  • [27] Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer
    Liu, Qipeng
    Wang, Guangyu
    Li, Qiaqia
    Jiang, Weihua
    Kim, Jung-Sun
    Wang, Rui
    Zhu, Sen
    Wang, Xiaoju
    Yan, Lin
    Yi, Yang
    Zhang, Lili
    Meng, Qingshu
    Li, Chao
    Zhao, Dongyu
    Qiao, Yuanyuan
    Li, Yong
    Gursel, Demirkan B.
    Chinnaiyan, Arul M.
    Chen, Kaifu
    Cao, Qi
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (02) : 415 - 426
  • [28] EZH2, an epigenetic driver of prostate cancer
    Yang, Yeqing Angela
    Yu, Jindan
    PROTEIN & CELL, 2013, 4 (05) : 331 - 341
  • [29] Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer
    Anwar, Talha
    Gonzalez, Maria E.
    Kleer, Celina G.
    AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (05): : 774 - 783
  • [30] Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer
    Han, Zhengyang
    Rimal, Ujjwal
    Khatiwada, Prabesh
    Brandman, Jacob
    Zhou, Jun
    Hussain, Muhammad
    Viola, Ronald E.
    Shemshedini, Lirim
    ENDOCRINOLOGY, 2022, 164 (01)
12345